Letters Surrogate end point scrutiny A more evidence based approach to the use of surrogate end points in policy making BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6498 (Published 25 October 2011) Cite this as: BMJ 2011;343:d6498 Article Related content Metrics Responses Peer review Related articles Feature Surrogates under scrutiny: fallible correlations, fatal consequences Published: 15 August 2011; BMJ 343 doi:10.1136/bmj.d5160 See more Cancer drugs remain FDA approved despite lack of benefit, study finds BMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568 Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 Promise of new Alzheimer’s drug is dashed after lack of evidence BMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362 Cited by... What type of clinical evidence is needed to assess medical devices?Abstract Fulltext PDF
